A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis

Fabio Pellegrini, Massimiliano Copetti, Francesca Bovis, David Cheng, Robert Hyde, Carl de Moor, Bernd C. Kieseier, Maria Pia Sormani

Research output: Contribution to journalArticle

Abstract

Background: Stratified medicine methodologies based on subgroup analyses are often insufficiently powered. More powerful personalized medicine approaches are based on continuous scores. Objective: We deployed a patient-specific continuous score predicting treatment response in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: Data from two independent randomized controlled trials (RCTs) were used to build and validate an individual treatment response (ITR) score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. Results: The ITR score for the combined treatment groups versus placebo detected differential clinical response in both RCTs. High responders in one RCT had a cross-validated ARR ratio of 0.29 (95% confidence interval (CI) = 0.13–0.55) versus 0.62 (95% CI = 0.47–0.83) for all other responders (heterogeneity p = 0.038) and were validated in the other RCT, with the corresponding ARR ratios of 0.31 (95% CI = 0.18–0.56) and 0.61 (95% CI = 0.47–0.79; heterogeneity p = 0.036). The strongest treatment effect modifiers were the Short Form-36 Physical Component Summary, age, Visual Function Test 2.5%, prior MS treatment and Expanded Disability Status Scale. Conclusion: Our modelling strategy detects and validates an ITR score and opens up avenues for building treatment response calculators that are also applicable in routine clinical practice.

Original languageEnglish
JournalMultiple Sclerosis Journal
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Precision Medicine
Multiple Sclerosis
Randomized Controlled Trials
Confidence Intervals
Therapeutics
Recurrence
Relapsing-Remitting Multiple Sclerosis
Placebos
Medicine

Keywords

  • dimethyl fumarate
  • individual treatment response
  • Multiple sclerosis
  • personalized medicine
  • proof-of-concept
  • treatment algorithms

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis. / Pellegrini, Fabio; Copetti, Massimiliano; Bovis, Francesca; Cheng, David; Hyde, Robert; de Moor, Carl; Kieseier, Bernd C.; Sormani, Maria Pia.

In: Multiple Sclerosis Journal, 01.01.2019.

Research output: Contribution to journalArticle

Pellegrini, Fabio ; Copetti, Massimiliano ; Bovis, Francesca ; Cheng, David ; Hyde, Robert ; de Moor, Carl ; Kieseier, Bernd C. ; Sormani, Maria Pia. / A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis. In: Multiple Sclerosis Journal. 2019.
@article{5d8f82c50a5340459c99baaacc90bf65,
title = "A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis",
abstract = "Background: Stratified medicine methodologies based on subgroup analyses are often insufficiently powered. More powerful personalized medicine approaches are based on continuous scores. Objective: We deployed a patient-specific continuous score predicting treatment response in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: Data from two independent randomized controlled trials (RCTs) were used to build and validate an individual treatment response (ITR) score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. Results: The ITR score for the combined treatment groups versus placebo detected differential clinical response in both RCTs. High responders in one RCT had a cross-validated ARR ratio of 0.29 (95{\%} confidence interval (CI) = 0.13–0.55) versus 0.62 (95{\%} CI = 0.47–0.83) for all other responders (heterogeneity p = 0.038) and were validated in the other RCT, with the corresponding ARR ratios of 0.31 (95{\%} CI = 0.18–0.56) and 0.61 (95{\%} CI = 0.47–0.79; heterogeneity p = 0.036). The strongest treatment effect modifiers were the Short Form-36 Physical Component Summary, age, Visual Function Test 2.5{\%}, prior MS treatment and Expanded Disability Status Scale. Conclusion: Our modelling strategy detects and validates an ITR score and opens up avenues for building treatment response calculators that are also applicable in routine clinical practice.",
keywords = "dimethyl fumarate, individual treatment response, Multiple sclerosis, personalized medicine, proof-of-concept, treatment algorithms",
author = "Fabio Pellegrini and Massimiliano Copetti and Francesca Bovis and David Cheng and Robert Hyde and {de Moor}, Carl and Kieseier, {Bernd C.} and Sormani, {Maria Pia}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1352458519849513",
language = "English",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis

AU - Pellegrini, Fabio

AU - Copetti, Massimiliano

AU - Bovis, Francesca

AU - Cheng, David

AU - Hyde, Robert

AU - de Moor, Carl

AU - Kieseier, Bernd C.

AU - Sormani, Maria Pia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Stratified medicine methodologies based on subgroup analyses are often insufficiently powered. More powerful personalized medicine approaches are based on continuous scores. Objective: We deployed a patient-specific continuous score predicting treatment response in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: Data from two independent randomized controlled trials (RCTs) were used to build and validate an individual treatment response (ITR) score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. Results: The ITR score for the combined treatment groups versus placebo detected differential clinical response in both RCTs. High responders in one RCT had a cross-validated ARR ratio of 0.29 (95% confidence interval (CI) = 0.13–0.55) versus 0.62 (95% CI = 0.47–0.83) for all other responders (heterogeneity p = 0.038) and were validated in the other RCT, with the corresponding ARR ratios of 0.31 (95% CI = 0.18–0.56) and 0.61 (95% CI = 0.47–0.79; heterogeneity p = 0.036). The strongest treatment effect modifiers were the Short Form-36 Physical Component Summary, age, Visual Function Test 2.5%, prior MS treatment and Expanded Disability Status Scale. Conclusion: Our modelling strategy detects and validates an ITR score and opens up avenues for building treatment response calculators that are also applicable in routine clinical practice.

AB - Background: Stratified medicine methodologies based on subgroup analyses are often insufficiently powered. More powerful personalized medicine approaches are based on continuous scores. Objective: We deployed a patient-specific continuous score predicting treatment response in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: Data from two independent randomized controlled trials (RCTs) were used to build and validate an individual treatment response (ITR) score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. Results: The ITR score for the combined treatment groups versus placebo detected differential clinical response in both RCTs. High responders in one RCT had a cross-validated ARR ratio of 0.29 (95% confidence interval (CI) = 0.13–0.55) versus 0.62 (95% CI = 0.47–0.83) for all other responders (heterogeneity p = 0.038) and were validated in the other RCT, with the corresponding ARR ratios of 0.31 (95% CI = 0.18–0.56) and 0.61 (95% CI = 0.47–0.79; heterogeneity p = 0.036). The strongest treatment effect modifiers were the Short Form-36 Physical Component Summary, age, Visual Function Test 2.5%, prior MS treatment and Expanded Disability Status Scale. Conclusion: Our modelling strategy detects and validates an ITR score and opens up avenues for building treatment response calculators that are also applicable in routine clinical practice.

KW - dimethyl fumarate

KW - individual treatment response

KW - Multiple sclerosis

KW - personalized medicine

KW - proof-of-concept

KW - treatment algorithms

UR - http://www.scopus.com/inward/record.url?scp=85066841350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066841350&partnerID=8YFLogxK

U2 - 10.1177/1352458519849513

DO - 10.1177/1352458519849513

M3 - Article

AN - SCOPUS:85066841350

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

ER -